Unicycive Therapeutics Q1 net loss widens on warrant liability

Unicycive Therapeutics

12/05/2026 12:12

Overview

U.S. kidney disease biotech reported Q1 net loss widened mainly due to warrant liability changes

R&D expense fell while G&A costs rose in Q1 2026

Result Drivers

R&D EXPENSES - Lower research and development costs due to reduced drug development and consulting fees

G&A EXPENSES - Higher general and administrative costs from increased consulting, professional services, and labor

WARRANT LIABILITY - Net loss increase mainly due to change in fair value of warrant liability

Company press release: ID:nGNXbkHB8j

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$12.82 mln
Q1 Income from Operations
-$8.44 mln
Q1 Operating Expenses
$8.44 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $31.00, about 289.9% above its May 11 closing price of $7.95

The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)